February’s top 10 includes a consensus statement from the Society for Vascular Surgery (SVS) and the Enhanced Recovery after Surgery (ERAS) Society on perioperative care in open aortic surgery, an enrolment update on Concept Medical’s SIRONA head-to-head trial of sirolimus versus paclitaxel drug-eluting balloon angioplasty in the femoropopliteal artery, and a study highlighting the need to extend the scope of cerebrovascular health disparities research.
1. Perioperative care in open aortic surgery: SVS and ERAS Society issue consensus statement
The Society for Vascular Surgery (SVS) and the Enhanced Recovery after Surgery (ERAS) Society have released a consensus statement intended to help address perioperative challenges faced by vascular surgery patients.
2. SIRONA head-to-head randomised trial achieves 50% enrolment
Concept Medical recently announced that the SIRONA randomised controlled trial (RCT)—a head-to-head comparison of sirolimus versus paclitaxel drug-eluting balloon angioplasty in the femoropopliteal artery—has completed half the targeted enrolment.
3. New technique outperforms manual assessment of thoracic aortic aneurysm growth
Researchers have developed a novel method of measuring growth of thoracic aortic aneurysm, which they claim could significantly improve the accuracy and reliability of aortic measurements compared to standard-of-care measurement techniques.
The Vascular Society Amputation Special Interest Group (SIG) recently held a remote UK multi-stakeholder meeting, including surgeons, physiotherapists, prosthetists, orthotists, occupational therapists and rehabilitation consultants, to discuss the place of through-knee amputation (TKA) surgery in today’s vascular practice. Robert Hinchliffe (North Bristol NHS Trust, Bristol, UK) and David Bosanquet (Royal Gwent Hospital, Newport, UK), chair and co-chair of the SIG, respectively, give an overview of the meeting for Vascular News.
5. Study highlights need to extend scope of cerebrovascular health disparities research
A new research letter in Stroke outlines use of the novel National Institutes of Health (NIH) ‘All of Us’ research programme dataset of diverse participant data to identify factors that increase the risk of carotid artery stenosis and those who undergo revascularisation. The study, authored by Daniela Renedo (Yale School of Medicine, New Haven, USA) and colleagues, includes electronic health record data from over 200,000 US patients.
6. MedAlliance acquires Japanese partner MDK Medical
MedAlliance has acquired its partner MDK Medical, a Japanese vascular specialist company. MDK Medical has previously worked closely with MedAlliance in developing Japanese clinical studies for its novel sirolimus drug-eluting balloon (DEB) Selution SLR in the treatment of peripheral arterial disease (PAD).
7. Worldwide TCAR analysis provides “roadmap” to evaluate future training approaches
An analysis of the worldwide experience of transcarotid artery revascularisation (TCAR) has produced key objective proficiency metrics and an analytic framework to assess adequate training for the procedure. “Training on cadavers or synthetic models achieved clinical outcomes, technical outcomes and proficiency measures for subsequently performed TCAR procedures similar to those achieved with training using traditional proctoring on live cases,” Brajesh K Lal (University of Maryland, Baltimore, USA) and colleagues conclude in the Journal of Vascular Surgery (JVS).
8. RapidAI announces Karim Karti as new CEO
RapidAI has announced Karim Karti, former president and CEO of GE Healthcare Imaging, as the company’s chief executive officer (CEO). Karim Karti comes to RapidAI with more than 25 years of experience in the medical technology industry and a demonstrated ability of growing companies and helping them achieve key milestones, a company press release details.
9. Front Line Medical expands availability of COBRA-OS aortic occlusion device
Front Line Medical Technologies has announced the expanded availability and distribution of COBRA-OS (Control of bleeding, resuscitation, arterial occlusion system), as US and Canadian hospitals continue to implement the aortic occlusion device during various surgical and emergency cases.
10. Cardiovascular Systems partners with Innova Vascular to develop full line of thrombectomy devices
Cardiovascular Systems Inc (CSI) recently announced it has partnered with Innova Vascular (Innova) to develop a full line of novel thrombectomy devices. According to a press release, CSI intends to acquire and commercialise novel thrombectomy devices from Innova targeting peripheral vascular disease, including deep vein thrombosis (DVT) and pulmonary embolism (PE).
